Global Respiratory Drugs Market 2017-2023: Global Revenue

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
116
Global Respiratory Drugs Market 2017-2023: Global Revenue from the Respiratory Market is Forecast to Increase from $30.9 Billion in 2016 to $41.3 Billion in 2023, at a CAGR of 4.23%

Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers" report has been added to Research and Markets' offering. Global Respiratory Drugs Market to 2023 provides the following analysis:

  • Provides introduction to respiratory disorders, including disease epidemiology, symptoms, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided. The chapter concludes with an analysis of the general treatment options.
  • Provides overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the respiratory disorders pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: leukemia, lymphoma and myeloma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to respiratory disorder products. Some of the most prominent deals are discussed in detail.

Respiratory disorders, which affect components of the respiratory system such as the lungs and airway, are a broad range of chronic diseases with a variety of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate the muscles surrounding the bronchial tubes to relax and open the airways.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)'s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate). The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex. Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging. In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

Scope

  • Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
  • The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
  • There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
  • The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
  • There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

Key Topics Covered:

1 Table of Contents 2 Introduction 2.1 Therapy Area Introduction 2.2 Symptoms 2.3 Diagnosis 2.3.1 Asthma 2.3.2 Chronic Obstructive Pulmonary Disease 2.3.3 Idiopathic Pulmonary Fibrosis 2.3.4 Cystic Fibrosis 2.4 Etiology and Pathophysiology 2.4.1 Asthma 2.4.2 Chronic Obstructive Pulmonary Disease 2.4.3 Idiopathic Pulmonary Fibrosis 2.4.4 Cystic Fibrosis 2.5 Epidemiology 2.5.1 Asthma 2.5.2 Chronic Obstructive Pulmonary Disease 2.5.3 Idiopathic Pulmonary Fibrosis 2.5.4 Cystic Fibrosis 2.6 Prognosis and Disease Staging 2.6.1 Asthma 2.6.2 Chronic Obstructive Pulmonary Disease 2.6.3 Idiopathic Pulmonary Fibrosis 2.6.4 Cystic Fibrosis 2.7 Treatment 2.7.1 Asthma 2.7.2 Chronic Obstructive Pulmonary Disease 2.7.3 Idiopathic Pulmonary Fibrosis 2.7.4 Cystic Fibrosis 3 Key Marketed Products 3.1 Overview 3.2 Advair - GSK 3.3 Symbicort - AstraZeneca/Astellas 3.4 Spiriva - Boehringer Ingelheim 3.5 Xolair - Roche/Novartis 3.6 Ventolin - GSK 3.7 Pulmicort - Astra Zeneca 3.8 Orkambi - Vertex 3.9 Relvar/Breo Ellipta - GSK 3.10 Singulair - Merck & Co. 3.11 Esbriet - Roche 3.12 Kalydeco - Vertex 3.13 Conclusion 4 Pipeline Landscape Assessment 4.1 Overview 4.2 Pipeline Development Landscape 4.3 Molecular Targets in the Pipeline 4.4 Clinical Trials 4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 4.5 Assessment of Key Pipeline Products 4.5.1 Ivacaftor and Tezacaftor - Vertex 4.5.2 (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva 4.5.3 Dupixent - Regeneron Pharmaceuticals/Sanofi 4.5.4 Benralizumab - AstraZeneca/Medimmune 4.5.5 Tralokinumab - AstraZeneca 4.5.6 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics 4.5.7 Conclusion 4.6 Conclusion 5 Multi-scenario Market Forecast to 2023 5.1 Overall Market Size 5.2 Generic Penetration 5.3 Revenue Forecast by Molecular Target 5.3.1 G Protein-Coupled Receptors 5.3.2 Immune/Inflammatory Mediators 5.3.3 Transcription Factors 5.3.4 Signal Transduction 5.3.5 CFTR Modulator 6 Company Analysis and Positioning 6.1 Revenue and Market Share Analysis by Company 6.1.1 GlaxoSmithKline 6.1.2 Vertex 6.1.3 AstraZeneca 6.1.4 Roche 6.1.5 Boehringer Ingelheim 6.1.6 Novartis 6.1.7 Teva 6.1.8 Sumitomo Dainippon 6.1.9 Regeneron 6.1.10 Merck & Co. 6.2 Company Landscape 6.3 Marketed and Pipeline Portfolio Analysis 7 Strategic Consolidations 7.1 Licensing Deals 7.1.1 Deal by Region, Year and Value 7.1.2 Deals by Stage of Development and Value 7.1.3 Deals by Molecule Type and Molecular Target 7.1.4 Table for Licensing Deals Valued Above $100m 7.2 Co-development Deals 7.2.1 Deals by Region, Year and Value 7.2.2 Deals by Stage of Development and Value 7.2.3 Deals by Molecule Type, Mechanism of Action and Value 7.2.4 Table for Co-development Deals Valued Above $100m 8 Appendix 8.1 Bibliography 8.2 All Pipeline Drugs by Phase 8.2.1 Discovery 8.2.2 Preclinical 8.2.3 IND/CTA-Filed/Phase 0 8.2.4 Phase I 8.2.5 Phase II 8.2.6 Phase III 8.2.7 Pre-registration 8.3 Abbreviations 8.4 Methodology

Companies Mentioned

  • Astra Zeneca
  • Astellas
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • Regeneron
  • Roche
  • Sumitomo Dainippon
  • Teva
  • Vertex

For more information about this report visit https://www.researchandmarkets.com/research/255hng/global

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics, Respiratory Drugs, Respiratory Drugs, Biopharmaceuticals , Asthma Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 175

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 34

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 16

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 211

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 0

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 120

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 0

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

A.B. Data Appoints Steve Straub as New Operations VP

Updated Category News Views 542

A.B. Data Appoints Steve Straub as New Operations VP A.B. Data, a prominent name in class action notice and claims administration, has elevated Steve Straub to the role of Vice President of Operations. Having served as the Senior Director of Operations since 2023, Steve brings a wealth of experience that will further strengthen the company’s operations. Strategic...

Continue Reading
Conexon Connect Expands Fiber Network for Rural Internet Access

Updated Category News Views 170

Conexon Connect's Milestone Achievement Conexon Connect has successfully completed a transformative fiber-to-the-home (FTTH) project, expanding high-speed internet access to over 12,000 members of rural electric cooperatives. This expansive network marks a significant achievement in bridging the digital divide, particularly for underserved communities. Partnerships...

Continue Reading
Xiaomi MIX Flip 2 Unveils TCL CSOT's Cutting-Edge Displays

Updated Category News Views 349

TCL CSOT Powers the Xiaomi MIX Flip 2's Display Experience TCL CSOT is making waves in the tech world by providing state-of-the-art displays for the Xiaomi MIX Flip 2. This new foldable smartphone marks a significant shift in user experiences, aligning perfectly with the growing demand for portable, high-performance devices. During a recent launch event showcasing...

Continue Reading
Immunic Showcases Promising Results for Vidofludimus Calcium

Updated Category News Views 106

Immunic Highlights Key Findings from CALLIPER Trial Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company specializing in innovative oral therapies for neurologic and gastrointestinal conditions, recently presented significant data from its Phase 2 CALLIPER trial. This trial evaluates its cornerstone therapy, vidofludimus calcium (IMU-838), aimed at treating...

Continue Reading
Amrop Expands Global Reach with New Office in Colombia

Updated Category News Views 153

Amrop Expands With a New Office in Colombia Amrop, a distinguished global executive search and leadership consulting firm, has recently announced the establishment of a new office in Colombia. This expansion marks a significant milestone for Amrop as they enhance their service offerings in Latin America. Introducing Amrop Colombia Amrop Colombia emerges from the merger...

Continue Reading